Asthma

Human Trial of Antisense Oligonucleotide Begins

Published in Gene Therapy Weekly, November 16th, 2000

EpiGenesis Pharmaceuticals Inc., Cranbury, New Jersey, announced that it has begun a randomized, double-blind, first-in-man, Phase I study to assess tolerability and pharmacokinetics of inhaled EPI-2010 for asthma.

EPI-2010 is a respirable antisense oligonucleotide (RASON), which pre-clinical studies have suggested can prevent the body's manufacture of certain disease-causing receptor proteins.

The EPI-2010 approach is to prevent asthma symptoms rather than to wait for the patient to suffer symptoms then treat them. EPI-2010 targets the adenosine A1 receptor, which is unique among mediators of asthma in that it is produced in excess in virtually all...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-11-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry